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Abstract 
Background: The influence of intensive glucose control in diabetic patients on the macrovascular outcomes is 
controversial. Thus, this study aimed to elucidate the effect of preprocedural hemoglobin A1c (HbA1c) on clinical 
outcomes after endovascular therapy for lower extremity artery disease (LEAD) in diabetic patients.
Methods: Diabetic patients were enrolled from the retrospective cohorts of a Korean multicenter endovascular 
therapy registry and were divided according to the HbA1c level during index admission into the optimal (< 7.0%) or 
suboptimal (≥ 7.0%) glycemic control groups. The primary endpoints were major adverse limb events (MALE, a com‑
posite of major amputation, minor amputation, and reintervention).
Results: Of the 1103 patients enrolled (897 men, mean age 68.2 ± 8.9 years), 432 (39.2%) were classified into the 
optimal glycemic control group and 671 (60.8%) into the suboptimal glycemic control group. In‑hospital events and 
immediate procedural complications were not different between the two groups. The suboptimal group showed a 
trend towards a higher incidence of MALE than the optimal group (log‑rank p = 0.072). Although no significant differ‑
ences were found between the two groups in terms of overall survival or amputation, the risk of reintervention was 
significantly higher in the suboptimal group (log‑rank p = 0.048). In the multivariate Cox regression model, suboptimal 
glycemic control was one of the independent predictors for reintervention. When our data were analyzed according 
to the initial presentation, suboptimal preprocedural HbA1c significantly increased the incidence of MALE compared 
with optimal preprocedural HbA1c only in patients with intermittent claudication.
Conclusion: In diabetic patients undergoing endovascular therapy for LEAD, suboptimal preprocedural HbA1c is 
associated with an increased risk of adverse limb events, especially in patients with intermittent claudication. Further 
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Background
Diabetes mellitus (DM) is associated with the devel-
opment of peripheral artery disease (PAD) [1]. Both 
the duration and severity of DM are associated with 
increased risk of PAD [2, 3]. The prognosis of PAD is 
worse in DM patients than in non-DM patients. Infra-
popliteal arterial involvement is more common and the 
need for a major amputation is higher in DM patients 
than in non-DM patients [4, 5].
The cardiovascular effect of intensive glucose control 
on the macrovascular events among DM patients is con-
troversial. In randomized trials, intensive glucose control 
in DM patients did not reduced major cardiovascular 
events compared with standard glucose management 
[6–8]. However, several studies suggested that poor gly-
cemic control at the time of peripheral angioplasty was 
associated with worse clinical outcomes in patients with 
critical limb ischemia (CLI) [9, 10]. In a recent retrospec-
tive analysis of US veterans undergoing lower extremity 
revascularization, patients with lower extremity artery 
disease (LEAD) and poor glycemic control were at higher 
risk of amputation and modified major adverse limb 
events than were those with good glycemic control [11].
The present study aimed to investigate the effect of 
suboptimal preprocedural hemoglobin A1c (HbA1c) 
on clinical outcomes of endovascular therapy in LEAD 




The Korean Vascular Intervention Society Endovascular 
therapy in Lower Limb Artery diseases (K-VIS ELLA) 
registry is a multicenter observational study with retro-
spective and prospective cohorts of patients with lower 
extremity artery disease treated with endovascular ther-
apy (ClinicalTrials.gov NCT02748226). The retrospec-
tive patient cohort consisted of 3434 patients with 5097 
affected limbs treated between January 2006 and July 
2015 in 31 Korean hospitals. The K-VIS ELLA registry 
study design and results have been described in detail 
previously [12]. A total of 3073 patients with 3972 target 
limbs were finally analyzed after exclusion of 56 limbs 
with acute limb ischemia, 82 limbs with Buerger’s dis-
ease, 11 limbs lacking procedural or in-hospital data, 528 
limbs lacking follow-up data after hospital discharge, and 
448 limbs treated for repeat revascularization following 
the index procedure.
From this registry population, 1103 DM patients (1420 
limbs) who had HbA1c levels available during index 
admission were finally included in the current analysis 
(Fig.  1). HbA1c levels were dichotomized into optimal 
(< 7.0%) and suboptimal (≥ 7.0%) according to American 
Diabetes Association recommendations [13]. Data on 
patient demographics, baseline clinical and lesion char-
acteristics, medication history, clinical presentation, lab-
oratory test results, treatments, and follow-up outcomes 
were collected from electronic medical records.
The study protocol was approved by the institutional 
review board of each hospital and was conducted accord-
ing to the principles of the Declaration of Helsinki. The 
institutional review boards of the participating hospitals 
waived the requirement of informed consent due to the 
retrospective nature of the study.
Definitions and study endpoints
LEAD was defined as the presence of ≥ 50% narrowing 
of a lower extremity artery. Claudication was defined 
as Rutherford category 1, 2, or 3 disease and CLI was 
defined as Rutherford category 4, 5, or 6 disease [14]. The 
presence of diabetes was identified by history and medi-
cal records including outpatient clinics and prescriptions 
of oral hypoglycemic agents or insulin. Definitions of 
hypercholesterolemia, smoking, congestive heart failure, 
anemia, and chronic kidney disease were described in a 
previous report [12].
Technical success was defined as successful revascu-
larization with residual stenosis < 30% and absence of 
flow-limiting dissection or a hemodynamically significant 
translesion pressure gradient. Major amputation was 
defined as any lower extremity amputation at the level of 
or above the ankle, and a minor amputation was defined 
as any lower extremity amputation below the ankle, 
including the foot or toe(s).
The primary endpoints of this study were major 
adverse limb events (MALE; a composite of major ampu-
tation, minor amputation, and reintervention). Second-
ary endpoints were all-cause mortality, any amputation, 
and reintervention. These outcomes were compared 
between optimal glycemic control and suboptimal glyce-
mic control groups according to the HbA1c level during 
the index admission.
prospective research will be required to validate the role of more intensive glycemic control on the reduction of 
adverse limb events in diabetic patients undergoing endovascular therapy for LEAD.
Keywords: Peripheral artery disease, Endovascular treatment, Diabetes mellitus, Glycated hemoglobin A, Glucose 
control, Clinical outcomes
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Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation and were compared using the Student’s t-test 
for parametric data and the Mann–Whitney test for non-
parametric data. Categorical variables were expressed as 
number (percentage) and were compared using the Chi 
square test or Fisher’s exact test. Data were analyzed on 
a per-patient basis for clinical characteristics and on a 
per-lesion basis for the limb, lesion, or procedural char-
acteristics. Cumulative incidences of clinical events were 
presented as Kaplan–Meier estimates and were com-
pared using the log-rank test. Univariate Cox propor-
tional hazards regression analyses using baseline clinical, 
lesion, and procedural variables were performed to iden-
tify factors associated with clinical events. The variables 
achieving P-values < 0.20 in the univariate analysis were 
evaluated in the multivariate analysis model to determine 
the independent predictors of clinical events. All statis-
tical analyses were performed using SPSS (version 23.0; 
IBM Corp., Armonk, NY, USA). All tests were two-sided, 
and P < 0.05 was considered statistically significant.
Results
Baseline characteristics
Baseline clinical characteristics of patients according to 
HbA1c levels during index admission are summarized in 
Table 1. Of the 1103 patients enrolled, 432 (39.2%) were 
categorized into the optimal glycemic control group 
(HbA1c < 7.0) and 671 (60.8%) were placed into the sub-
optimal glycemic control group (HbA1c ≥ 7.0). The mean 
age of the entire cohort was 68.2 ± 8.9  years, and 897 
(81.3%) patients were men. Compared with the patients 
in the suboptimal group, those in the optimal group were 
older, were predominantly male, and had a higher preva-
lence of chronic kidney disease and congestive heart fail-
ure. Patients in the suboptimal group were more likely to 
be on insulin therapy for glycemic control. Initial clinical 
presentations based on the Rutherford classification were 
not different between the two groups.
Procedural characteristics and complications
Table  2 demonstrates baseline lesion and procedural 
characteristics according to HbA1c levels during the 
index admission. No significant differences were found 
between the groups except that there were slightly more 
targeted blood vessels in the suboptimal group. Total in-
hospital events and immediate procedural complications 
were not different between the two groups (Fig. 2).
Follow‑up clinical outcomes and independent predictors
The median follow-up duration was 724  days (inter-
quartile range 326–782 days). The Kaplan–Meier curves 
in Fig.  3 illustrate freedom from MALE, death, ampu-
tation, and reintervention stratified by initial HbA1c 
status. The suboptimal group showed a trend toward 
higher incidence of MALE than the optimal group (log-
rank p = 0.072, Fig.  3a). No significant differences were 
observed between the two groups in terms of overall sur-
vival (Fig. 3b) or amputation (Fig. 3c) during the follow-
up period. However, the suboptimal group demonstrated 
Fig. 1 Study population flow chart. DM diabetes mellitus, HbA1c hemoglobin A1c
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a significant disadvantage with regard to reintervention 
(log-rank p = 0.048, Fig.  3d). In the multivariate Cox 
regression model, the use of insulin for glycemic control, 
end-stage renal disease, previous history of amputation, 
previous history of endovascular therapy, and CLI were 
independent predictors of MALE (Table  3). Independ-
ent predictors for reintervention during follow-up were 
end-stage renal disease, previous history of endovascu-
lar therapy, and suboptimal glycemic control defined as 
HbA1c ≥ 7.0% (Table 4).
Influence of preprocedural HbA1c levels on clinical 
outcomes according to the initial presentation
To assess the influence of preprocedural HbA1c levels on 
clinical outcomes according to the initial clinical presen-
tation, we analyzed data separately in patients with inter-
mittent claudication or CLI (Fig. 4). Among CLI patients, 
no difference was found in the incidence of MALE 
between the optimal and suboptimal groups (Fig.  4a). 
However, among patients who presented with claudica-
tion, the suboptimal group showed a higher incidence 




We reported the association between the preproce-
dural glycemic control based on HbA1c during index 
admission and clinical outcomes in DM patients 
undergoing endovascular therapy for LEAD. Although 
not statistically significant, the suboptimal glyce-
mic control group (HbA1c ≥ 7.0) showed a tendency 
towards higher incidence of MALE than in the opti-
mal glycemic control group (HbA1c < 7.0). Elevated 
preprocedural HbA1c was associated with higher risk 
of reintervention. Suboptimal glycemic control was 
an independent predictor of reintervention during 
the follow-up period after endovascular therapy in 
DM patients with LEAD. Because CLI was one of the 
independent predictors for MALE, we further ana-
lyzed our data by dividing it into the presence of clau-
dication and CLI according to the initial presentation. 
Table 1 Baseline clinical characteristics
Values are presented as mean ± standard deviation or number (%) unless otherwise stated
BMI body mass index, EVT endovascular therapy
Total (n = 1103) HbA1c < 7.0 (n = 432) HbA1c ≥ 7.0 (n = 671) p
Age (years) 68.2 ± 8.9 69.4 ± 8.9 67.5 ± 8.7 0.001
Old age (≥ 80 years) 96 (8.7%) 48 (11.1%) 48 (7.2%) 0.028
Male 897 (81.3%) 365 (84.5%) 532 (79.3%) 0.033
Hemoglobin A1c (%) 7.6 ± 1.6 6.3 ± 0.5 8.5 ± 1.4 < 0.001
BMI (kg/m2) 24.1 ± 3.8 24.0 ± 3.9 24.2 ± 3.7 0.607
Low BMI (< 18.5 kg/m2) 46 (4.4%) 19 (4.7%) 27 (4.2%) 0.757
Hypertension 870 (78.9%) 347 (80.3%) 523 (77.9%) 0.365
Use of Insulin 361 (32.7%) 109 (25.2%) 252 (37.6%) < 0.001
Hypercholesterolemia 426 (38.6%) 176 (40.7%) 250 (37.3%) 0.255
Current smoker 288 (26.1%) 101 (23.4%) 187 (27.9%) 0.106
Chronic kidney disease 279 (25.3%) 124 (28.7%) 155 (23.1%) 0.040
End‑stage renal disease 166 (15.0%) 72 (16.7%) 94 (14.0%) 0.262
Coronary artery disease 653 (59.2%) 263 (60.9%) 390 (58.1%) 0.380
Congestive heart failure 57 (5.2%) 30 (6.9%) 27 (4.0%) 0.037
Previous history of stroke 185 (16.8%) 81 (18.8%) 104 (15.5%) 0.161
Previous history of EVT 99 (9.0%) 46 (10.6%) 53 (7.9%) 0.131
Previous history of bypass surgery 28 (2.5%) 10 (2.3%) 18 (2.7%) 0.845
Previous history of amputation 81 (7.3%) 33 (7.6%) 48 (7.2%) 0.813
Rutherford classification 0.201
 1 89 (8.1%) 40 (9.3%) 49 (7.3%)
 2 259 (23.5%) 106 (24.5%) 153 (22.8%)
 3 272 (24.7%) 106 (24.5%) 166 (24.7%)
 4 80 (7.3%) 33 (7.6%) 47 (7.0%)
 5 236 (21.4%) 80 (18.5%) 156 (23.2%)
 6 167 (15.1%) 67 (15.5%) 100 (14.9%)
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Suboptimal preprocedural HbA1c did not affect the 
outcome in CLI patients; however, among those with 
intermittent claudication, suboptimal preprocedural 
HbA1c significantly increased the incidence of MALE 
compared with optimal glycemic control.
Role of glycemic control on vascular outcomes
The role of intensive glucose control on the macrovascu-
lar outcomes in DM patients is unclear. Although large 
randomized controlled trials failed to demonstrate the 
benefits of intensive glucose control in reducing major 
Table 2 Baseline lesion and procedural characteristics
Values are presented as mean ± standard deviation or number (%) unless otherwise stated
TASC II Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease II Classifications
Total (n = 1420 limbs) HbA1c < 7.0 (n = 547 limbs) HbA1c ≥ 7.0 (n = 873 limbs) p
Ankle brachial index 0.7 ± 0.3 0.7 ± 0.3 0.7 ± 0.3 0.777
TASC II classification 0.543
 A 224 (15.8%) 95 (17.4%) 129 (14.8%)
 B 310 (21.8%) 122 (22.3%) 188 (21.5%)
 C 304 (21.4%) 114 (20.8%) 190 (21.8%)
 D 582 (41.0%) 216 (39.5%) 366 (41.9%)
Number of target vessels 1.5 ± 0.7 1.4 ± 0.6 1.5 ± 0.8 0.006
Target vessels 0.058
 Aortoiliac 461 (32.5%) 192 (35.1%) 269 (30.8%)
 Femoropopliteal 666 (46.9%) 253 (46.3%) 413 (47.3%)
 Infrapopliteal 293 (20.6%) 102 (18.6%) 191 (21.9%)
Total occlusion 592 (41.7%) 235 (43.0%) 357 (40.9%) 0.472
In‑stent restenosis 45 (3.2%) 20 (3.7%) 25 (2.9%) 0.438
Treatment modality 0.918
 Balloon only 582 (41.0%) 219 (40.0%) 363 (41.6%)
 Stent 810 (57.0%) 321 (58.7%) 489 (56.0%)
 Others 28 (2.0%) 7 (1.3%) 21 (2.4%)
Lesion length (mm) 111.7 ± 97.6 111.1 ± 96.1 112.1 ± 98.6 0.856
Diameter stenosis (%) 88.0 ± 14.1 88.4 ± 14.4 87.9 ± 14.0 0.553
Fig. 2 In‑hospital outcomes and procedural complication rates according to HbA1c level during index admission. Crude incidence of death, 
reintervention, amputation, bleeding complication, access site complication, distal embolization, and vascular rupture for optimal (blue) and 
suboptimal (red) glucose control groups. HbA1c hemoglobin A1c
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cardiovascular events [6–8], recent post hoc analyses 
of several randomized trials demonstrated that higher 
HbA1c was associated with increased risk of major car-
diovascular events [15, 16] and lower extremity amputa-
tion [17].
For the management of LEAD, recent practice guide-
lines recommended adequate glycemic control in DM 
patients [18–20], and several retrospective observa-
tional studies suggested that poor glycemic control may 
be associated with worse clinical outcomes of vascular 
procedure in DM patients with LEAD. In a single-center 
study of 278 CLI patients undergoing balloon angioplasty, 
Takahara et al. reported that the presence of diabetes was 
independently associated with major amputation and, in 
the DM subgroup, poor glycemic control was associated 
with higher amputation rates [9]. Similarly, in another 
single-center study, Singh et al. analyzed the effect of pre-
procedural fasting blood glucose on primary patency and 
limb outcomes following infrapopliteal balloon angio-
plasty in 149 DM patients with CLI [10]. They found 
that fasting blood glucose above the median value at the 
time of the procedure was associated with lower primary 
patency at 1 year [10]. However, these were single-center 
studies with relatively small sample size and only CLI 
patients were enrolled. Therefore, the results cannot be 
generalized to all LEAD patients.
Fig. 3 Comparison of clinical outcomes according to HbA1c level during index admission. Kaplan–Meier curves for comparison of freedom from 
MALE (a), death (b), amputation (c), and reintervention (d). HbA1c hemoglobin A1c, MALE major adverse limb events
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Recently, Arya et  al. reported a large retrospective 
study using Veterans Health Administration data to eval-
uate the influence of elevated perioperative HbA1c on 
outcomes in LEAD patients undergoing surgical or endo-
vascular revascularization procedures [11]. In that study, 
high HbA1c level was incrementally associated with 
higher risk of amputation and MALE regardless of the 
preoperative diagnosis of DM [11]. In the present study, 
we found no significant differences between the two 
groups in terms of risk of amputation or MALE, although 
the suboptimal group showed a trend toward higher 
incidence of MALE than the optimal group. Compared 
with the aforementioned studies, the relatively lower 
incidence of amputation in our study groups may be one 
Table 3 Independent predictors of major adverse limb events
BMI body mass index, CI confidence interval, EVT endovascular therapy, HbA1c hemoglobin A1c, HR hazard ratio
Univariable analysis Multivariable analysis
HR 95% CI p‑value HR 95% CI p‑value
Age (per 10 years) 0.824 0.702–0.967 0.018 0.887 0.748–1.051 0.167
Sex (female) 1.200 0.847–1.700 0.306
Low BMI (< 18.5 kg/m2) 1.732 0.965–3.109 0.066 0.593 0.329–1.071 0.083
Hypertension 0.815 0.587–1.130 0.219
Use of insulin 1.944 1.462–2.585 < 0.001 1.386 1.020–1.885 0.037
Hypercholesterolemia 0.836 0.622–1.123 0.234
End‑stage renal disease 2.727 1.960–3.794 < 0.001 1.776 1.238–2.546 0.002
Congestive heart failure 1.622 0.957–2.749 0.073 1.563 0.903–2.705 0.111
Current smoker 0.658 0.464–0.933 0.019 0.711 0.495–1.022 0.065
Coronary artery disease 1.131 0.784–1.632 0.509
Previous history of stroke 0.743 0.414–1.333 0.319
Previous history of Bypass surgery 1.150 0.473–2.796 0.758
Previous history of amputation 2.526 1.681–3.796 < 0.001 1.564 1.016–2.408 0.042
Previous history of EVT 1.667 1.101–2.526 0.016 1.858 1.210–2.853 0.005
Critical limb ischemia 2.472 1.845–3.312 < 0.001 1.970 1.426–2.723 < 0.001
HbA1c ≥ 7.0% 1.319 0.975–1.786 0.073 1.269 0.927–1.738 0.137
Table 4 Independent predictors of reintervention
BMI body mass index, CI confidence interval, EVT endovascular therapy, HbA1c hemoglobin A1c, HR hazard ratio
Univariable analysis Multivariable analysis
HR 95% CI P‑value HR 95% CI P‑value
Age (per 10 years) 0.963 0.790–1.174 0.709
Sex (female) 1.018 0.816–1.271 0.872
Low BMI (< 18.5 kg/m2) 1.445 0.674–3.098 0.344
Hypertension 0.740 0.502–1.091 0.128 0.767 0.516–1.140 0.189
Use of insulin 1.394 0.978–1.987 0.066 1.147 0.789–1.668 0.472
Hypercholesterolemia 1.182 0.834–1.675 0.346
End‑stage renal disease 1.725 1.095–2.718 0.019 1.719 1.074–2.753 0.024
Congestive heart failure 1.225 0.598–2.506 0.579
Current smoker 0.899 0.607–1.330 0.593
Coronary artery disease 0.699 0.495–0.987 0.042 0.863 0.584–1.274 0.458
Previous history of stroke 1.023 0.646–1.618 0.924
Previous history of bypass surgery 1.846 0.754–4.518 0.180 1.598 0.637–4.009 0.318
Previous history of amputation 1.547 0.872–2.745 0.136 1.172 0.649–2.118 0.598
Previous history of EVT 2.230 1.406–3.537 0.001 2.333 1.455–3.740 < 0.001
Critical limb ischemia 1.194 0.839–1.700 0.325
HbA1c ≥ 7.0% 1.458 1.001–2.123 0.049 1.473 1.005–2.160 0.047
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of the reasons for the differences. Furthermore, the sub-
jects of Arya et al.’s study were veterans, most of whom 
were male, and approximately 40% of the subjects were 
not diagnosed with DM preoperatively. Furthermore, 
LEAD severity was not specified in more than a third of 
the enrolled patients. These might be possible reasons for 
the discrepancies between our results and those of Arya 
et  al. Recent studies in patients undergoing open vas-
cular surgery demonstrated that poor glycemic control 
was associated with earlier postoperative outcomes such 
as in-hospital limb events [21] or 30-day mortality [22, 
23]. Compared with the results from studies in patients 
undergoing endovascular therapy, earlier effect of poor 
glycemic control on postoperative outcomes observed in 
patients undergoing vascular surgery may be attributed 
to surgery-related complications such as wound compli-
cations or postoperative infections.
When our data were analyzed separately in two groups 
according to initial presentation, the benefit of opti-
mal glycemic control in reducing the risk of MALE was 
observed only in patients presenting with claudication. 
Considering the seriousness of the CLI as an independ-
ent risk factor for MALE, intensive glucose control pos-
sibly did not significantly reduce the incidence of MALE 
in CLI patients. Relatively lower incidence of amputation 
in our study may also have affected the results. A recent 
study evaluated the association between preoperative 
HbA1c levels and clinical outcomes after lower extrem-
ity bypass surgery and found that poor preoperative 
glycemic control increased the risk of in-hospital limb 
events [21]. Similar to our findings, the increased risk for 
adverse limb events in patients with high preoperative 
HbA1c level was only observed in patients without CLI 
[21].
Other factors related to PAD outcomes
In addition to HbA1c, various biomarkers have been sug-
gested to be related to clinical outcomes of PAD in DM 
patients. Zhao et  al. investigated the association of vas-
cular damage with the triglyceride-glucose index as a 
simple surrogate marker of insulin resistance [24]. They 
demonstrated that an increased triglyceride-glucose 
index was significantly associated with a higher risk of 
arterial stiffness and renal microvascular damage, but not 
with PAD [24]. Biscetti et al. demonstrated that circulat-
ing sortilin levels were associated with the presence and 
severity of LEAD in statin-naïve DM patients [25]. Bis-
cetti et  al. found that omentin-1 serum levels were sig-
nificantly lower in DM patients with PAD than in DM 
patients without PAD, and omentin-1 levels were related 
to disease severity [26]. Elevated levels of various inflam-
matory cytokines such as osteoprotegerin, tumor necro-
sis factor-a, interleukin-6, and C-reactive protein were 
also reported to be related with worse vascular outcomes 
in DM patients with LEAD undergoing infrapopliteal 
endovascular therapy [27]. These potential surrogate bio-
markers may be helpful to better stratify PAD risk in DM 
patients. Their usefulness should be confirmed in future 
studies.
Fig. 4 Comparison of MALE according to HbA1c level during index admission. Kaplan–Meier curves for comparison of freedom from MALE in 
patients with critical limb ischemia (a) or intermittent claudication (b). HbA1c hemoglobin A1c, MALE major adverse limb events
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In addition to molecular biomarkers, several clinical 
confounding factors may influence on clinical outcomes 
of LEAD in DM patients. It has been shown that women 
with LEAD have more functional impairment and worse 
outcomes than men [28]. Although these gender differ-
ences were not observed in the present study population, 
in a previous study performed on the entire cohort from 
our registry, women had higher rates of major adverse 
cardiovascular events and MALE [29]. Frailty is also 
associated with poor clinical outcomes after vascular 
interventions for LEAD [30], although increasing num-
bers of peripheral vascular intervention for older patients 
was shown to correlate with decreasing major amputa-
tion rates [31].
Limitations
This study has several limitations. First, given the ret-
rospective nature of the study, the causal relationships 
could not be determined. Therefore, prospective rand-
omized trials will be required to validate the role of more 
intensive glycemic control on the reduction of adverse 
limb events in DM patients with LEAD undergoing endo-
vascular therapy. Second, the HbA1c level that we used as 
the basis of glycemic control was measured once before 
the procedure, and data on changes in glycemic control 
during the follow-up period were not available. There-
fore, dramatic changes in blood glucose levels during 
follow-up may have affected the clinical outcomes. How-
ever, HbA1c reflects the average blood glycemic level 
over approximately 3 months [13], and the measurement 
of HbA1c was performed during the index admission in 
all cases. At least our data highlight the importance of 
glycemic control during preprocedural period. Third, the 
strategy for hyperglycemia management was not stand-
ardized. Recent studies have shown that novel glucose-
lowering agents can reduce the risk of cardiovascular 
events in patients with atherosclerotic cardiovascular dis-
ease [32]. However, increased risk of lower limb ampu-
tation has been reported for certain sodium-glucose 
cotransporter type-2 inhibitors in patients with LEAD 
[33]. For these reasons, the optimal method of glycemic 
control is an important topic to be addressed in future 
studies.
Conclusion
In DM patients undergoing endovascular therapy for 
LEAD, suboptimal preprocedural HbA1c is associated 
with increased risk of adverse limb events, especially in 
patients with intermittent claudication. Future research 
will have to determine whether more intensive glycemic 
control can improve clinical outcomes after endovascular 
therapy in DM patients with LEAD.
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